Skip to main content

Table 1 Patient characteristics by analysis cohort

From: Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

  Trial VIII Trial IX Pooled Trials
p53 Analyzed Not analyzed Analyzed Not analyzed Analyzed Not analyzed
Number of patients 417 646 696 973 1,113 1,619
Median age (range) 46 45 61 60   
  (26 to 58) (22 to 56) (42 to 77) (34 to 81)   
   ns   ns   
ER status, n       
Absent 84 101 128 137 212 238
> = 1% 322 360 558 516 880 876
Missing 11 185 10 320 21 505
   ns1   ns   
Tumor size, n       
0 to 1 cm 27 99 65 136 92 235
> 1 to 2 cm 206 321 333 450 539 771
> 2 cm 182 217 280 352 462 569
Missing 2 9 18 35 20 44
   P < 0.0001   P = 0.01   
Tumor grade, n       
  52 94 85 160 137 254
1 171 286 304 447 475 733
2 168 179 248 261 416 440
3 26 87 59 105 85 192
Missing   P = 0.002   P = 0.0004   
10-year DFS 71.3% 76.0%
P = 0.152
67.6% 75.5%
P = 0.10
  
10-year OS 86.4% 87.4%
P = 0.44
81.1% 83.8%
P = 0.65
  
  1. 1P-values compare distribution of non-missing values between analyzed and non-analyzed cohorts; ns, not significant. 2DFS and OS P-values based on logrank comparison of entire curves. n, number of patients; DFS, disease-free survival; OS, overall survival.